Glioblastoma patients treated with bevacizumab experience reduced cognitive function and quality of life

Many glioblastoma patients treated with bevacizumab (Avastin®) have significant deterioration in neurocognitive function, symptoms and quality of life. Not only that, the changes often predict treatment outcomes, according to new research from The University of Texas MD Anderson Cancer Center. The findings from the large national multi-center Phase III trial, RTOG 0825, were presented at the annual meeting of the American Society of Clinical Oncology. Read more here.